09/06/2024 7:02 PM | Apogee Therapeutics (Issuer) HENDERSON MICHAEL THOMAS (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/06/2024 7:03 PM | Apogee Therapeutics (Issuer) Dambkowski Carl (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/04/2024 12:35 PM | Apogee Therapeutics (Subject) HENDERSON MICHAEL THOMAS (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
08/23/2024 7:05 PM | Apogee Therapeutics (Issuer) Henderson Jane (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
08/19/2024 6:29 AM | Apogee Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
08/12/2024 4:25 PM | Apogee Therapeutics (Filer)
| Form S-3ASR | |
08/12/2024 6:00 AM | Apogee Therapeutics (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
|
08/12/2024 5:35 AM | Apogee Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
08/09/2024 7:05 PM | Apogee Therapeutics (Issuer) HENDERSON MICHAEL THOMAS (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
08/09/2024 7:05 PM | Apogee Therapeutics (Issuer) Dambkowski Carl (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
08/07/2024 12:18 PM | Apogee Therapeutics (Subject) HENDERSON MICHAEL THOMAS (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/05/2024 7:01 PM | Apogee Therapeutics (Issuer) Dambkowski Carl (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
07/05/2024 7:01 PM | Apogee Therapeutics (Issuer) HENDERSON MICHAEL THOMAS (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
07/05/2024 12:39 PM | Apogee Therapeutics (Subject) HENDERSON MICHAEL THOMAS (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/03/2024 12:13 PM | Apogee Therapeutics (Subject) Dambkowski Carl (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
06/07/2024 7:12 PM | Apogee Therapeutics (Issuer) JONES WILLIAM A JR (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/07/2024 7:00 PM | Apogee Therapeutics (Issuer) Fairmount Funds Management LLC (Reporting) Harwin Peter Evan (Reporting) Kiselak Tomas (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/07/2024 7:01 PM | Apogee Therapeutics (Issuer) Gottesdiener Andrew (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/07/2024 7:02 PM | Apogee Therapeutics (Issuer) Shah Nimish P (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/07/2024 7:03 PM | Apogee Therapeutics (Issuer) Fox Jennifer A. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/07/2024 7:04 PM | Apogee Therapeutics (Issuer) Bollinger Lisa (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/07/2024 7:05 PM | Apogee Therapeutics (Issuer) McKenna Mark C. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/30/2024 7:05 PM | Apogee Therapeutics (Issuer) Bollinger Lisa (Reporting)
| Form 3 Initial statement of beneficial ownership of securities | |
05/30/2024 7:07 PM | Apogee Therapeutics (Issuer) Bollinger Lisa (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/28/2024 6:35 AM | Apogee Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/28/2024 6:36 AM | Apogee Therapeutics (Filer)
| Form DEFA14A | |
05/15/2024 3:39 PM | Apogee Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/13/2024 6:10 AM | Apogee Therapeutics (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
05/13/2024 6:26 AM | Apogee Therapeutics (Filer)
| Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
05/13/2024 6:05 AM | Apogee Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
04/24/2024 3:15 PM | Apogee Therapeutics (Filer)
| Form DEF 14A | |
04/24/2024 3:16 PM | Apogee Therapeutics (Filer)
| Form DEFA14A | |
04/24/2024 3:18 PM | Apogee Therapeutics (Filer)
| Form ARS | |
04/01/2024 4:42 PM | Apogee Therapeutics (Subject) Fairmount Funds Management LLC (Filed by)
| Form SC 13D/A | |
04/01/2024 4:44 PM | Apogee Therapeutics (Issuer) Fairmount Funds Management LLC (Reporting) Fairmount Healthcare Fund II L.P. (Reporting) Fairmount Healthcare Fund L.P. (Reporting) Harwin Peter Evan (Reporting) Kiselak Tomas (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/25/2024 6:30 AM | Apogee Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
03/11/2024 5:01 AM | Apogee Therapeutics (Filer)
| Form 424B4 | |
03/07/2024 11:15 PM | Apogee Therapeutics (Filer)
| Form EFFECT | |
03/07/2024 5:27 PM | Apogee Therapeutics (Filer)
| Form S-1MEF | |
03/05/2024 7:15 AM | Apogee Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
03/05/2024 5:11 AM | Apogee Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
Who are Nvidia’s New Silent Partners? (Ad) Nvidia knows it can’t stand still as AI continues to grow at an exponential rate.
That’s why CEO Jensen Huang consistently has his company ahead of the curve when it comes to artificial intelligence.
Nvidia’s added $2 trillion in market cap in 2024. I call these Nvidia’s “Silent Partners.” |
03/05/2024 5:15 AM | Apogee Therapeutics (Filer)
| Form 10-K Annual report pursuant to Section 13 or 15(d) | |
02/14/2024 7:35 AM | Apogee Therapeutics (Subject) Deep Track Capital, LP (Filed by)
| Form SC 13G/A | |
02/09/2024 7:35 AM | Apogee Therapeutics (Subject) FMR LLC (Filed by)
| Form SC 13G/A | |
01/31/2024 3:30 PM | Apogee Therapeutics (Subject) Fairmount Funds Management LLC (Filed by)
| Form SC 13D/A | |
01/31/2024 3:31 PM | Apogee Therapeutics (Issuer) Fairmount Funds Management LLC (Reporting) Fairmount Healthcare Co-Invest II L.P. (Reporting) Fairmount Healthcare Fund II L.P. (Reporting) Fairmount Healthcare Fund L.P. (Reporting) Harwin Peter Evan (Reporting) Kiselak Tomas (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/20/2023 7:00 PM | Apogee Therapeutics (Issuer) HENDERSON MICHAEL THOMAS (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/20/2023 7:00 PM | Apogee Therapeutics (Issuer) Henderson Jane (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/20/2023 7:01 PM | Apogee Therapeutics (Issuer) Dambkowski Carl (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
11/13/2023 6:41 AM | Apogee Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
11/13/2023 6:45 AM | Apogee Therapeutics (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |